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ABSTRACT
Incidence of percutaneous exposure to hepatitis C virus (HCV) is still quite high, particularly in medical 
staffs. Though not all will cause infection, but if acute HCV infection occurs, it usually develops into chronic 
hepatitis which finally causes cirrhosis and hepatocellular carcinoma. Untill now, there is no standard method 
either in regiments, administration time, or duration of administration to prevent HCV infection after exposure 
occurs, as well as the use of antiviral therapy in acute HCV. HCV therapy target is viral eradication, thus the 
therapy response is defined using virological parameter than clinical parameter.
Different from hepatitis B virus (HBV), immunoglobulin administration after exposure to HCV is not 
recommended as it is not proven to prevent transmission, similarly with pegylated interferon (PEG-IFN) or 
interferon (IFN) administration. In addition, several studies concluded that risk of HCV transmission after 
percutaneous exposure is low, therefore regular strict monitoring (monthly in the first 16 weeks after exposure) 
to clinical and laboratory results (HCV-RNA, alanine aminotransferase) is more required, so that detection and 
early treatment to acute HCV can be performed, considering that several studies showed that early monotherapy 
using IFN/PEG-IFN in acute HCV could reach quite high sustained virological response (SVR). 
Keywords: hepatitis C, post exposure prophylaxis, acute infection treatment 
ABSTRAK
Insiden paparan perkutaneus terhadap hepatitis C virus (HCV) masih cukup tinggi, terutama di kalangan 
petugas medis. Walaupun tidak semua akan menyebabkan infeksi, namun apabila terjadi infeksi HCV akut, 
maka seringkali dapat berkembang menjadi hepatitis kronik yang akhirnya dapat menimbulkan sirosis dan 
karsinoma hepatoseluler. Hingga saat ini belum ada metode baku baik dalam hal regimen, waktu pemberian, 
maupun lama pemberian untuk pencegahan infeksi HCV setelah terjadinya paparan. Begitu pula dengan terapi 
antivirus pada HCV akut. Target terapi HCV adalah eradikasi virus, sehingga respon terapi lebih didefinisikan 
dengan parameter virulogik daripada parameter klinis.
Berbeda dengan hepatitis B virus (HBV), pemberian imunoglobulin paska paparan terhadap HCV bukan 
merupakan rekomendasi karena tidak terbukti mencegah transmisi, begitupula dengan pemberian pegylated 
interferon (PEG-IFN) ataupun interferon (IFN). Selain itu dari beberapa studi juga disimpulkan bahwa risiko 
transmisi HCV setelah paparan perkutaneus adalah rendah, sehingga pemantauan berkala yang ketat (setiap 
bulan dalam 16 minggu pertama setelah paparan) terhadap klinis dan hasil laboratorium (HCV-RNA, alanin 
amino transferase) lebih diperlukan agar deteksi dan terapi dini terhadap HCV akut dapat dilakukan, mengingat 
beberapa studi menunjukkan bahwa monoterapi dini menggunakan IFN/PEG-IFN pada HCV akut dapat mencapai 
respon virulogi menetap yang cukup tinggi. 
Kata kunci: hepatitis C, profilaksis paska paparan, terapi infeksi akut
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INTRODUCTION
Incidence of percutaneous exposure, such as 
through syringe-needle or open wound, is a potential 
cause of communicable infectious disease transmission 
through blood in health care workers. Based on data 
from disease control and prevention (CDC) USA 
(2000), at least 600,000 health workers in United 
States experienced percutaneous exposure every year. 
This happens due to mistakes in syringe-needle 
insertion technique, closing used syringe-needles, and 
way to dispose syringe-needles or mistakes in the use 
of protective equipments, such as not using gloves or 
using gloves with inappropriate size. Agustian et al, 
conducted a study to estimate the transmission risk of 
hepatitis B virus (HBV), hepatitis C virus (HCV), and 
human immunodeficiency virus (HIV) infection among 
medical staffs in Indonesia. Study results revealed 
that the estimation of infection in year 2005 due to 
percutaneous exposure was 1,445 people for HBV, 399 
people for HCV, and 18 people for HIV.1 
Acute HCV infection often developed into chronic 
hepatitis which may finally cause cirrhosis and 
hepatocellular carcinoma, therefore the progressivity 
prevention effort of this disease become very 
important. Till date, there is no standard method 
either in regiments, administration time, or even 
administration duration to prevent HCV infection 
after being exposed; similarly with the use of antiviral 
therapy in acute HCV. Few studies recommended 
early therapy in acute condition to achieve sustained 
virological response (SVR). However, the right time 
to initiate therapy is still controversial because in 
15-30%, acute hepatitis C could heal spontaneously 
(self-limited). Several predictor factors in spontaneous 
HCV clearance have been studied, but generally 
the study was not performed with big sample size 
and good prospective study design.2 This review will 
elaborate the benefit and risk of antiviral therapy for 
HCV prophylaxis after percutaneous exposure and 
antiviral therapy for acute hepatitis C.
NATURAL PROGRESSION OF HEPATITIS C
HCV infection may cause acute or chronic 
hepatitis. Acute hepatitis usually does not cause 
symptoms (asymptomatic). However, if it present 
with symptoms, they usually subside in few weeks. 
Acute HCV infection is generally defined as new 
viremia incidence which is marked with conversion 
of HCV-RNA negative to HCV-RNA positive. 
In the serum, HCV-RNA can be detected in 
1-2 weeks after exposure. Anti-HCV seroconversion 
can be detected in 2-6 months (window period) or even 
could be more than six months in particular group, thus 
anti-HCV examination to diagnose acute HCV become 
inappropriate if compared to HCV-RNA test. Acute 
phase of HCV infection is erected in the first six months 
and in 20-50%, spontaneous resolution may occur, 
while in the other 50-80%, chronic HCV will develop. 
In chronic HCV, 20% will develop into cirrhosis, 
6% into end-stage liver disease, while the other 14% 
into hepatocellular carcinoma.3,4 
TREATMENT SUCCESS CRITERIA
HCV therapy target is viral eradication, as an 
effort to prevent complication of the disease, such as 
necroinflammation, fibrosis, cirrhosis, hepatocellular 
carcinoma, and mortality. If HCV is eradicated, 
then necroinflammation process will not continue 
and cirrhosis progression will be ceased in non-
cirrhosis patient, thus therapy response is more 
defined with virological parameter rather than clinical 
parameter. Virological response, is divided into several 
types based on achievement time to therapy target 
(Table 1).4,5 Short term therapy response can be 
measured biochemically (normalization of ALT serum), 
virologically (no detection of HCV-RNA serum), and 
histologically (improvement in inflammatory score and 
no worsening of fibrosis score).5 
PROPHYLAXIS THERAPY AFTER PERCUTANEOUS 
EXPOSURE
Public health service USA in 2001 published 
guidelines on management of prophylaxis after 
occupation exposure to HBV, HCV, and HIV. In that 
guideline, it was explained that different from HBV, 
immunoglobulin administration after occupation 
exposure to HCV was not recommended. Results 
of several studies which evaluated the efficacy of 
immunoglobulin to HCV exposure were difficult 
to be interpreted because difference in diagnostic 
criteria or even study design.6 An experimental 
study using chimpanzees which were injected with 
high titer anti-HCV immunoglobulin in one hour 
after exposure to blood containing HCV, obtained 
that this was not proved to prevent transmission of 
HCV infection.7
Corey et al, performed a prospective study on 
prophylaxis after HCV exposure to 51 health care 
workers in Massachusetts, Boston, who experienced 
exposure to HCV patients’ blood.8 Prophylaxis therapy 
was given to 44 subjects who were willing to receive 
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pegylated interferon (PEG-IFN) α-2b 1 µg/kg body 
weight, subcutaneously, weekly for four weeks, since 
seven days after exposure. Four weeks duration was 
chosen because based on the available study, it was 
estimated that this duration was the fastest duration 
which gave out good efficacy, besides preventing the 
presence of side effects to interferon. Ribavirin was not 
given due to the numbers of reproductive age female 
participated in this study. Study results showed that 
none experienced HCV viremia or HCV antibody 
seroconversion at the end of therapy or in week 4 after 
therapy. Similarly, in the group who did not receive 
prophylaxis therapy, in the same period of time, HCV 
viremia or HCV antibody seroconversion was not 
found. In the group who received therapy, side effects 
were reported, such as flulike symptoms 41 (93%) 
subjects, headache 31 (70%) subjects, irritation on 
injection site 26 (59%) subjects, and mood depression 
in 3 (6.81%) subjects.8 
Nukaya et al, conducted a survey to subjects who 
experienced exposure to blood (through syringe needles, 
surgical knife, or blood splashes) in Social Insurance 
Chukyo, Tokyo between 1993-2003, which was aimed 
to evaluate the benefit of recombinant IFN-α2b 10 
MU single administration intramuscularly to prevent 
transmission.9 This study concluded that prophylaxis 
benefit with that regiment was unclear, therefore there 
was no importance to administer IFN prophylaxis 
therapy. Continuous observation particularly in high 
risk cases was highly recommended, thus the therapy 
could be administered as soon as possible if acute 
hepatitis was revealed.9 
Chung et al, performed a study to 684 health care 
workers who experienced occupation exposure (syringe-
needles or surgical knife) to patients with anti-HCV 
positive. From 684 subjects, 279 (41%) were given 
IFN therapy directly after exposure or in 1-12 days after 
exposure. Administration duration was around 1-3 days. 
In three months of observation, one incidence of acute 
HCV was found in each group; therapy group (1/279; 
0.4%) and non-therapy group (1/405; 0.2%). Therefore, 
it was concluded that HCV transmission risk after 
exposure to syringe-needles was low, and prophylaxis 
therapy with IFN in short duration was not needed.10
THERAPY OF ACUTE HEPATITIS
Kamal et al, conducted a study to 161 patients 
proven to suffer from acute HCV and 23% apparently 
experienced spontaneous resolution. In univariate 
analysis, age less than 30 years, onset of symptoms, 
and HCV-RNA less than 800,000 IU/mL were 
associated with spontaneous resolution, while in 
multivariate analysis only appearance of symptoms 
was a significant predictor of spontaneous resolution.11
Until now, optimal strategy therapy for acute HCV 
is still a controversy, considering the possibility of 
spontaneous resolution and the absence of symptoms 
in most cases. But actually there are several factors 
which are quite rational to be considered in therapy 
administration, such as the high incidence of acute 
infection which developed into chronic and the absence 
of definite predictors on acute infection prognosis. 
Compared to acute HCV, chronic HCV is related with 
Table 1. Therapy response based on virological parameter4,5
Virological response Definition Clinical benefits
Rapid virological response (RVR) HCV RNA (-) in week 4 therapy using sensitive PCR-
based quantitative assay
 
Can be used as a consideration to shorten 
therapy in genotype 2 & 3 and in genotype 
1 with low viral load
Early virological response (EVR) Partial EVR:
HCV-RNA level reduction ≥ 2 log compared to 
baseline HCV-RNA level
Complete EVR:
HCV RNA (-) in week 12 therapy
Predicting SVR failure
End of treatment response (ETR) HCV-RNA (-) in the end of therapy (24 or 48 weeks)
Sustained virological response (SVR) HCV-RNA (-) after 24 weeks of therapy cessation Best predictors of long term therapy 
response
Breakthrough Re-emergence of HCV-RNA in the serum when the 
therapy is ongoing 
Relapse Re-emergence of HCV-RNA in the serum after therapy 
is ceased
Non-responder Failure to eradicate HCV-RNA in the serum after 24 
weeks therapy
Null-responder (NR) Reduction of HCV-RNA level < 2log10 IU/mL from the 
baseline after 12 weeks therapy
Partial-responder (PR) Reduction of HCV-RNA level > 2log10 IU/mL from the 
baseline after 12 weeks  baseline after therapy but 
HCV-RNA is still detected in week 12 and 24
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bad prognosis, need of intensive therapy with PEG-IFN 
and ribavirin, long therapy duration, and decrease of 
therapy success rate. Conversely, intervention in acute 
phase is associated with the success of viral eradication, 
use of monotherapy regiments which have better 
tolerability, low price, more comfortable, and shorter 
duration of treatment.3
THERAPY SELECTION
Acute HCV Monotherapy with IFN-α
Several studies on IFN-α2b monotherapy for acute 
HCV gave out SVR between 53-100%. However, due 
to difference in inclusion criteria, sample size which 
is usually small, patients heterogenicity, absence 
of control, different type and dosage of interferon, 
difference in definition of therapy response, and 
inadequate observation time to eliminate long term 
relapse, made us difficult to interpret those study results 
(Table 2).12-15
Acute HCV Monotherapy with Pegylated Interferon-α
Several clinical trials on benefit and safety usage of 
PEG-INFα as acute HCV therapy have been performed 
(Table 3). Transmission model in most cases in these 
studies was use of intravenous drugs, exposure to 
syringe-needles, medical procedures, or sexual contact 
with person known to suffer from hepatitis C.11,16-19 
After therapy using PEG-IFNα-2b monotherapy for 
12-24 weeks, thus the average range of SVR was 
71-95%, depends on the population, HCV genotype, 
therapy onset, and adherence to therapy.3 
Time to Initiate Therapy
Based on the literature, the best time to start acute 
HCV therapy has not been known precisely. Several 
clinical trials started therapy in different times, varying 
between 1-24 months after onset of symptoms, first 
detection of HCV-PCR, or when seroconversion 
occurred.
Kamal et al, conducted a study to 168 acute HCV 
patients. In 129 patients known to not experience 
spontaneous healing in week 8, randomization was 
performed to obtain PEG-IFN α-2b monotherapy 
(1.5 µg/kg/week) which was started at week 8, 12, or 
20 with 12 weeks of administration duration. Study 
results showed that in the group, in which therapy was 
initiated at week 8 (43 subjects), week 12 (43 subjects), 
and in week 20 (43 subjects), the SVR achievements 
were 95%, 92%, and 76%, respectively. Overall, SVR 
achievement was better in those infected with genotype 
2, 3 and 4 compared to genotype 1. However, among 
those infected with HCV genotype 1 and had high viral 
load, earlier therapy initiation resulted in better SVR 
achievement.17 Delwaide et al, performed a prospective 
study to assess the benefits of early therapy using 
IFN-α 2b in acute HCV. Study results showed that early 
therapy since onset of symptoms was the most relevant 
predictor in SVR achievement (Table 4).15
Combination of IFNα or PEG-IFNα and Ribavirin
Prospective study carried out by Kamal et al, 
exhibited the absence of significant difference between 
PEG-IFNα monotherapy and combination therapy of 
PEG-IFN-α and ribavirin as acute HCV monotherapy 
in terms of SVR. This study performed observation 
to 54 acute HCV patients, who were divided into 
3 groups, which are group who received PEG-IFN α 
plus ribavirin (n = 20), monotherapy PEG-IFN group 
(n = 20), and group who did not receive therapy 
(n = 14). After 24 weeks therapy, it was obtained that 
there was no significant difference in SVR achievement 
(p = 0.27) in group receiving combination of PEG-IFN 
plus ribavirin (SVR 85%) and PEG-IFN monotherapy 
group (SVR 80%), while in the group who did not 
receive therapy, 5 people was known to experience 
spontaneous healing.20
Kamal et al, conducted a prospective study on 
specific response of T CD4+ cell to HCV and cytokines 
production to various types of HCV proteins in the 
peripheral blood of 42 patients who received IFN 
α-2a, PEG-IFN α-2a monotherapy, or combination of 
PEG-IFN α-2a and ribavirin and its correlation to the 
success of therapy. Study results showed that SVR was 
significantly higher in the PEG-IFN group (42% in 
monotherapy PEG-IFN α-2a and 57% in combination 
PEG-IFN α-2a plus ribavirin) compared to IFN 
α-2a group (14%). In the success of PEG-IFN α-2a 
monotherapy or even in combination with ribavirin, 
in achieving SVR it was thought to be related with 
the high ability of PEG-IFN in inducing and maintaining 
response of T CD4+ specific cells to HCV.21
Rocca et al, performed a cohort study to 16 patients 
to evaluate transmission model and efficacy of antiviral 
therapy in acute HCV patients.22 Study results showed 
that among 13 patients receiving acute HCV therapy, 
12 patients who completed therapy have average SVR 
and biochemical response for more than 15 months 
after the therapy was ceased (about 4-36 months). 
Therapy duration, types of interferon, and combination 
with ribavirin did not give significant difference to 
therapy response. Thus, it could be concluded that early 
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intervention with IFNα was effective in preventing 
the progression of acute HCV infection to chronic in 
most patients without concerning about the therapy 
duration, types of interferon, or even combination 
with ribavirin.22
Wiegand et al, carried out a study which was aimed 
to analyze the benefit of early therapy in acute HCV 
with PEG-IFN α-2b. As many as 89 individuals with 
acute HCV infection received PEG-IFN-α 2b therapy 
for 24 weeks. Median of therapy initiation was 76 days 
after infection (14-150 days). From 65 (73%) patients 
who had good adherence (received 80% interferon dose 
and fulfilled 80% determined therapy duration), SVR 
achievement was 94%. From all analyzed variables (age, 
viral load, HCV genotype, bilirubin level, ALT level), 
only ALT level more than 500 U/L before therapy was 
the factor associated with therapy success (p < 0.025). 
From this study, it was concluded that early therapy with 
PEG-IFN α-2b in acute HCV infection patients with high 
adherence would result in high SVR.16
Kamal et al, made a recommendation on when to 
initiate therapy in acute HCV as follows in Figure 1.3
Duration of Therapy
Optimal duration for acute HCV therapy is still 
undecided. Guidelines by American Association for 
the Study of Liver Diseases (AASLD) stated that 
based on the current available information and study 
results, no definite recommendation about optimal 
duration required for acute HCV therapy could be 
made. However, it was stated that 12 weeks and 
24 weeks duration could be considered.5
Several clinical trials which have been performed 
using conventional IFN or even PEG-IFN, applied 
different duration with variable results, and most 
studies did not perform long enough observation to 
eliminate the possibility of long term relapse. From 
four clinical trials, it was obtained that 12 weeks 
duration of therapy in acute HCV could give SVR 
74-93%.11,17-19
Study results of Kamal et al, revealed that from 
102 acute HCV patients who received therapy for 8, 12, 
and 24 weeks, overall did not find significant difference 
between therapy duration and SVR achievement. 
However, if related with viral genotype, there was 
significant difference between therapy duration 
and SVR achievement in genotype-1 compared to 
other genotypes, in which 24 weeks therapy gave 
out better SVR achievement compared to 8 and 12 
weeks therapy. Further analysis to those infected with 
genotype oneobtained that 24 weeks therapy gave out 
much better SVR achievement in those who had high 
viral load or those who did not achieve RVR. Hence, 
from this study, it was concluded that therapy duration 
should be optimalized based on genotype, viral load, 
and also RVR achievement (Figure 2).11
 Baseline: Anti-HCV (-), HCV RNA, normal ALT 
HCV-PCR & antibody HCV/month for 12 weeks 
HCV-RNA (-) 
HCV-PCR at 16th-week 
Symptom (-) Symptom (+) 
Initial therapy 
Monotherapy PE-G
IFN for 12/14 weeks 
HCV-PCR at 16th-week 
HCV-RNA (+) 
HCV-RNA (-) HCV-RNA (+) 
Stop 
HCV-RNA (+) HCV-RNA (-) 
Stop 
Figure 1. Recommended algorithm of acute HCV management3
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Figure 2. SVR achievement related to therapy duration associated with genotype, also viral load in genotype 1 and 411
Table 4. Summary of studies which describe good sustained virulogical response in 12 weeks therapy duration11,17-19
Study type Cohort Transmission
HCV 
genotype 
(%)
Spontaneous 
clearance 
n/N (%)
Regiment
Initial
therapy 
(week)
Therapy 
duration 
(week)
SVR
n (%)
Non-random
De Rosa et al
n = 19
Most of 
asymptomatic 
(74%)
IVDU (74%)
Sexual contact 
(16%)
Syringe-needle 
(10%)
1 (58)
2/3 (42)
NA PEG-IFNα-
2b 1.06-
1.66 µg/ kg/
week
Average 
33.6 
days 
(range 
0-116 
days)
12 14/19 
(74)
Random
Kamal et al 
n = 168
Symptomatic & 
asymptomatic
Occupation 
exposure, 
medical 
procedure
1b (40)
2/3 (8)
4 (58)
31/141 (22) PEG-IFNα-
2b 1.5 µg/ 
kg
8 
12
20
12 41/43 
(95)
40/43 
(93)
33/43 
(77)
Kamal et al
n = 173
Symptomatic & 
asymptomatic
Occupation 
procedure, 
medical 
procedure
Most of  
4a and 1b
29/131 (22) PEG-IFNα-
2b 1.5 µg/ 
kg/week
12 8
12
24
23/34 
(68)
28/34 
(82)
31/34 
(91)
Unknown design
De Rosa et al
n = 23
Symptomatic 
asymptomatic
IVDU (100%) 1 (58)
2/3 (42)
NA PEG-IFN 
α-2b 1.33 
µg/kg/week
12 12 17/23 
(74)
IVDU: intravenous drug user; PEG-IFNα: pegylated interferon-α; NA: not applicable
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CONCLUSION
Based on the study results mentioned above, it 
can be concluded that HCV transmission risk after 
percutaneous exposure is low, and prophylaxis 
therapy with immunoglobulin or IFN is not required. 
If exposure occurs, it is better to directly perform HCV-
RNA, anti HCV, and ALT examinations as baseline 
data. Further, close regular monitoring (every month 
in the first 16 weeks after exposure) is performed to 
clinical and laboratory results (HCV-RNA, ALT) so 
therapy administration can be directly performed if 
acute HCV occur, considering that several studies 
showed that early monotherapy using IFN/PEG-IFN 
in this condition could reach quite high SVR. Regular 
monitoring can be ceased if after 16 weeks after 
exposure, HCV-RNA still gives out negative results.
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